Respiratory tract infections (RTIs) 
Abstract
Respiratory tract infections (RTIs) pneumoniae (CAP) and acute exacerbations of chronic bronchitis, which are associated with significant rates of mortality and are among the top 10 causes of death in developed world. In developing countries, infants under 4 years of age are at greatest risk of lower RTIs, whereas in developed countries the severity of infection and rate of mortality are greater in elderly. 7 There is no consensus regarding standard guideline/recommendation on use of cephalosporin in management of acute RTI (e.g. pneumonia and bronchitis) and the reference regimen varies in Bangladesh. Patients of acute RTI are managed with a wide of range of antibiotics, 3rd generation oral Cefixime may improve the effectiveness of the treatment due to their strong beta lactamase stability against respiratory pathogens.
The objective of the study was to describe the treatment pattern of third generation oral cefixime in managing RTIs in general practice. To assess also the clinical cure rate and occurance of adverse events.
Materials and Methods
This non-controlled, multicenter, observational registry was carried out from March 2009 to July 2010. During this period 2400 patients aged 3 years to 76 years suffering from RTIs were enrolled by general physicians throughout the country.
Patients included in this study were of different age, diagnosed with one or more RTIs. The tool used for study was a set of prepared questionnaire
Introduction
Respiratory tract infections (RTIs) are a major health problem in developing countries.
1 An estimated 2.2 million people, world wide, die yearly because of acute respiratory infections.
2 It is estimated that Bangladesh, India, Indonesia and Nepal together account for 40% of global acute respiratory infection mortality.
3 These respiratory infections can manifest in any area of the respiratory tract. As an infection of lungs, pneumonia is one of the major causes for ARI. About 90% of ARI deaths are due to pneumonia, which is usually bacterial in origin.
Common presenting signs and symptoms were fever and chills, cough, shortness of breath and increased sputum volume in 80%, 75%, 39%, and 12% respectively (Fig-1) From the laboratory diagnosis, pneumonia was found in majority of the cases (42.7%). Other cases were acute bronchitis (26.3%), acute exacerbation of chronic bronchitis (23.9%) and lung abscess (3%) respectively. (Fig-2) .
In most of the cases RTIs was diagnosed and treated by assessing clinical sign and symptoms. Chest X-ray was done in 35% patients. (Table 2) Many patients reported that they suffer from associated diseases along with RTIs. Increased frequency of exacerbation of chronic bronchitis (30%) and previous history of pneumonia (25%) were commonly present (Table 3 ).Many patients reported that they suffer from associated diseases along with RTIs. Increased frequency of exacerbation of chronic bronchitis (30%) and previous history of pneumonia (25%) were commonly present (Table 3) .
for each patient whose diagnosis was based on clinical evidence by the doctor and other diagnostic test reports and the technique adopted was personal interview with the patient. Individual patients were interviewed using the prepared questionnaire for this study after their visit to the doctor. All the prescriptions were returned to the patients after noting down the study variables. Verbal consent was taken from every patient before enrolling in the study. In case of minor, parents gave the consent. Patients with very severe infection who required hospitalization were excluded.
Study variable were socio demographic, signs and symptoms, clinical diagnosis, investigations carried out, antimicrobial prescribed and clinical outcome. Clinical outcome was determined based on improvement of signs and symptoms. Compliance, efficacy and tolerance were assessed on days 7 and 10.
Results
The enrolled 2400 patients were considered for analysis. The patients were between 3 to 76 years old and the mean age was 26.59(± 18.10) years. Among the patients 62% were male. The occurrence of RTI was higher among urban residents than semi-urban and rural residents 56%, 32% and 11% respectively. Among the patients only 15% were engaged in different professions but majority was non-professionals. From the patients 25% were The socio-demographic characteristics of the patients are summarized in Table 1 . 
Discussion
Total 2400 patients with RTIs were eligible for analysis. Pneumonia, acute bronchitis, acute exacerbation of chronic bronchitis and lung abscess were made in 42%, 26% 24% and 3% of the prescriptions. This represents close similarity to the other studied in different countries. 9, 10 Percentage of smoker was higher among patients of acute bronchitis and acute exacerbation of chronic bronchitis. Following treatment with cefixime, clinical cure, much improved and better was obtained in 77%, 21% and 2% respectively. Clinical symptoms improved rapidly and high rates of clinical cure were achieved and result showed with other studies. 11, 12 Furthermore, the rate of adverse events were relatively low in comparison with other studies.
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Conclusion
Cefixime is quickly establishing as a potent broadspectrum antibiotic with a variety of indications. The aim of the study was to obtain information on the clinical efficacy and safety of cefixime in the treatment of respiratory tract infections in children and adults in Bangladesh. The study showed clinical symptoms improved rapidly and high rates of clinical cure were achieved. In summary, the results supports the use of Cefixime for a variety of Respiratory infections in adult and pediatric patients in Bangladesh.
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